Abstract
Background: The long-term efficacy of biological agents in a Saudi population differs from other populations. Purpose: We studied 12 patients with moderate-to-severe psoriasis undergoing biological treatment to assess the long-term efficacy of these medications in the Saudi Arabian population. Methods: This retrospective study includes 12 patients diagnosed with moderate-to-severe psoriasis. The patients were followed up in a dermatology clinic in Riyadh, Saudi Arabia, from January 2019 to January 2020. Patients’ demographic data, psoriasis type, duration of biologic treatment, side effects, duration of remission and presence or absence of other medical conditions, and previous or concomitant medications were recorded. Results: Six adalimumab-treated patients sustained remission over 5–8 years, with relapses observed in two cases due to treatment nonadherence. Two other adalimumab-treated patients sustained remission for 10–11 years. Two adolescent boys receiving etanercept maintained remission for 3–6 years. A patient with guttate psoriasis who was initially resistant to adalimumab and etanercept was then managed with methotrexate. An adult female, maintained on infliximab infusions for a decade, is currently in remission. Conclusion: Genetic factors can influence treatment response. Data from larger datasets can support genetic research to personalize biological treatments.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call